Arthur F.  Ryan net worth and biography

Arthur Ryan Biography and Net Worth

Arthur F. Ryan serves as Independent Director of the Company. In 2008, Mr. Ryan retired as the Chairman of the Board of Prudential Financial, Inc., one of the largest diversified financial institutions in the world. He served as Chief Executive Officer of Prudential until 2007. Prior to joining Prudential in 1994, Mr. Ryan served as President and Chief Operating Officer of Chase Manhattan Bank since 1990. Mr. Ryan managed Chase’s worldwide retail bank between 1984 and 1990. From 2008 to 2013, Mr. Ryan served as a non-executive director of the Royal Bank of Scotland Group plc. From 2009 to 2019, Mr. Ryan served as a director of Citizens Financial Group, Inc., a retail bank holding company that became publicly traded in 2014, and also served as its lead director, chair of the Compensation and Human Resources Committee, and a member of the Nominating and Corporate Governance Committee. Mr. Ryan’s substantial leadership experience as a chief executive officer of leading companies in the banking and insurance industries, and his extensive business experience and financial expertise, led the board to conclude that Mr. Ryan should serve as a director.

What is Arthur F. Ryan's net worth?

The estimated net worth of Arthur F. Ryan is at least $16.40 million as of March 1st, 2024. Mr. Ryan owns 18,282 shares of Regeneron Pharmaceuticals stock worth more than $16,395,663 as of April 21st. This net worth approximation does not reflect any other assets that Mr. Ryan may own. Learn More about Arthur F. Ryan's net worth.

How do I contact Arthur F. Ryan?

The corporate mailing address for Mr. Ryan and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on Arthur F. Ryan's contact information.

Has Arthur F. Ryan been buying or selling shares of Regeneron Pharmaceuticals?

Arthur F. Ryan has not been actively trading shares of Regeneron Pharmaceuticals over the course of the past ninety days. Most recently, Arthur F. Ryan sold 100 shares of the business's stock in a transaction on Friday, March 1st. The shares were sold at an average price of $982.05, for a transaction totalling $98,205.00. Following the completion of the sale, the director now directly owns 18,282 shares of the company's stock, valued at $17,953,838.10. Learn More on Arthur F. Ryan's trading history.

Who are Regeneron Pharmaceuticals' active insiders?

Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Regeneron Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 30 times. They sold a total of 59,085 shares worth more than $51,077,528.46. The most recent insider tranaction occured on March, 14th when EVP Andrew J Murphy sold 5,783 shares worth more than $5,531,266.01. Insiders at Regeneron Pharmaceuticals own 8.8% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.

Information on this page was last updated on 3/14/2024.

Arthur F. Ryan Insider Trading History at Regeneron Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/1/2024Sell100$982.05$98,205.0018,282View SEC Filing Icon  
2/1/2024Sell100$954.22$95,422.0018,382View SEC Filing Icon  
12/1/2023Sell100$817.30$81,730.0018,447View SEC Filing Icon  
11/7/2023Sell100$827.90$82,790.0018,547View SEC Filing Icon  
8/1/2023Sell100$736.59$73,659.0018,647View SEC Filing Icon  
7/3/2023Sell100$716.88$71,688.0018,747View SEC Filing Icon  
6/1/2023Sell100$735.42$73,542.0018,847View SEC Filing Icon  
4/3/2023Sell100$819.31$81,931.0019,047View SEC Filing Icon  
3/1/2023Sell100$762.50$76,250.0019,147View SEC Filing Icon  
8/4/2022Sell10,453$621.29$6,494,344.3718,408View SEC Filing Icon  
5/2/2022Sell100$650.78$65,078.0022,182View SEC Filing Icon  
4/1/2022Sell100$692.81$69,281.0022,282View SEC Filing Icon  
2/1/2022Sell100$607.14$60,714.00View SEC Filing Icon  
12/1/2021Sell100$637.53$63,753.00View SEC Filing Icon  
10/1/2021Sell100$569.49$56,949.00View SEC Filing Icon  
7/1/2021Sell100$564.50$56,450.0023,589View SEC Filing Icon  
6/14/2021Sell100$524.76$52,476.0023,673View SEC Filing Icon  
12/1/2020Sell100$520.48$52,048.0023,741View SEC Filing Icon  
11/2/2020Sell100$548.54$54,854.0027,323View SEC Filing Icon  
8/3/2020Sell100$641.93$64,193.0028,640View SEC Filing Icon  
6/1/2020Sell100$603.23$60,323.0028,838View SEC Filing Icon  
5/1/2020Sell100$520.37$52,037.0028,931View SEC Filing Icon  
4/1/2020Sell100$483.85$48,385.0029,141View SEC Filing Icon  
3/30/2020Sell100$466.69$46,669.0029,141View SEC Filing Icon  
11/15/2016Sell2,000$429.34$858,680.0036,500View SEC Filing Icon  
5/24/2016Sell1,000$396.64$396,640.0040,500View SEC Filing Icon  
5/31/2013Sell2,500$249.55$623,875.00View SEC Filing Icon  
11/1/2012Sell10,000$145.57$1,455,700.00View SEC Filing Icon  
See Full Table

Arthur F. Ryan Buying and Selling Activity at Regeneron Pharmaceuticals

This chart shows Arthur F Ryan's buying and selling at Regeneron Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals logo
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Read More

Today's Range

Now: $896.82
Low: $891.46
High: $920.73

50 Day Range

MA: $953.01
Low: $893.99
High: $993.35

2 Week Range

Now: $896.82
Low: $684.80
High: $998.33

Volume

507,466 shs

Average Volume

412,356 shs

Market Capitalization

$98.43 billion

P/E Ratio

25.81

Dividend Yield

N/A

Beta

0.11